Bristol-myers Squibb Compnay

Viiv Healthcare UK (no. 4) Limited

Viiv Healthcare UK (no.5) Limited

Viiv Healthcare UK Limited

Brian Lee Venables

Ny Sin

Nicholas A Meanwell

Jie Chen

Sing-Yuen Sit

Alicia Regueiro-Ren

Jacob Swidorski

Yan Chen

Richard A Hartz

Paul Michael Scola

Zheng Liu

Yong-Jin Wu

Guanglin Luo

Carolyn Diane Dzierba

Junqing Guo

Amy C Hart

Jianliang Shi

Kuo-Long Yu

Rita Civiello

Xiangdong Alan Wang

Li Xu

Hatice Belgin Gulgeze

Keith D Combrink

Andrew Charles Good

Michael G Yang

Steven H Spergel

Zhiwei Yin

Yi Zhang

Zili Xiao

David Bertil Frennesson

Jan Willem Thuring

Ira B Dicker

Matthew Reiser Patton

Xirui Hu

Beata Nowicka-Sans

John E Macor

William John Pitts

Li-Qiang Sun

Scott Hunter Watterson

Jeffrey Allen Campbell

Alan Xiangdong Wang

Bradley C Pearce

Zhizhen Barbara Zheng

Hua Gong

Michael E Mertzman

Jason M Guernon

Carolyn A Weigelt

Murugaiah Andappan Murugaiah Subbaiah

Amy Ripka

Bradley C Pearc

Michael C Mertzman

Alicia Regueiro-ren

Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.

Triazolopyridinyl compounds as kinase inhibitors

The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications. 

Aminopyrrolotriazines as kinase inhibitors

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.

C-3 and C-17 modified triterpenoids as HIV-1 inhibitors

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from Ccycloalkyl, Ccycloalkenyl, Cspirocycloalkyl, Cspirocycloalkenyl, Coxacycloalkyl, Cdioxacycloalkyl, Coxacycloalkenyl, Cdioxacycloalkenyl, Ccyclodialkenyl, Coxacyclodialkenyl, Coxaspirocycloalkyl and Coxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is &#x2014;Calkyl-halo. These compounds are useful for the treatment of HIV and AIDS.

Triterpenoids with HIV maturation inhibitory activity

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I:  These compounds are useful for the treatment of HIV and AIDS.

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 and C-3 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.

C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the function of the NS3 protease (also referred to herein as 'serine protease') encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS3 protease.

The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.

The present invention concerns antiviral compounds, their methods of preparation and their compositions, and use in the treatment of viral infections. More particularly, the invention provides heterocyclic substituted 2-methylbenzimidazole derivatives for the treatment of respiratory syncytial virus infection.

Heterocyclic substituted 2-methyl-benzimidazole antiviral agents

Growing community of inventors

Durham, CT, United States of America

Brian Lee Venables